The ret proto-oncogene is consistently expressed in human pheochromocytomas and thyroid medullary carcinomas. 1990

M Santoro, and R Rosati, and M Grieco, and M T Berlingieri, and G L D'Amato, and V de Franciscis, and A Fusco
Centro di Endocrinologia ed Oncologia Sperimentale del CNR, II Facoltà di Medicina e Chirurgia, Università di Napoli, Italy.

We have recently reported the identification of a new oncogene, named PTC, frequently activated in human thyroid papillary carcinomas. This gene is a novel rearranged form of the ret proto-oncogene and we have shown that this rearrangement occurred in vivo as a tumor-specific somatic event. In an effort to further examine the role of this oncogene in human malignancies, we have investigated the expression of the ret oncogene in a number of human tumors. We consistently detected expression of normal-sized transcripts of the ret proto-oncogene in human pheochromocytomas and in human medullary thyroid carcinomas (MTC), both of familial and sporadic type. Moreover, we showed that ret mRNA levels were increased following (Bu)2cAMP-induced differentiation of a human MTC cell line (TT). Since the ret gene has been mapped on chromosome 10, close to the gene which predisposes patients to the MEN2A syndrome, we suggest that this region of chromosome 10 might be involved in the proliferative and differentiative patterns of these neuroectodermal tissues.

UI MeSH Term Description Entries
D010673 Pheochromocytoma A usually benign, well-encapsulated, lobular, vascular tumor of chromaffin tissue of the ADRENAL MEDULLA or sympathetic paraganglia. The cardinal symptom, reflecting the increased secretion of EPINEPHRINE and NOREPINEPHRINE, is HYPERTENSION, which may be persistent or intermittent. During severe attacks, there may be HEADACHE; SWEATING, palpitation, apprehension, TREMOR; PALLOR or FLUSHING of the face, NAUSEA and VOMITING, pain in the CHEST and ABDOMEN, and paresthesias of the extremities. The incidence of malignancy is as low as 5% but the pathologic distinction between benign and malignant pheochromocytomas is not clear. (Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1298) Pheochromocytoma, Extra-Adrenal,Extra-Adrenal Pheochromocytoma,Extra-Adrenal Pheochromocytomas,Pheochromocytoma, Extra Adrenal,Pheochromocytomas,Pheochromocytomas, Extra-Adrenal
D011505 Protein-Tyrosine Kinases Protein kinases that catalyze the PHOSPHORYLATION of TYROSINE residues in proteins with ATP or other nucleotides as phosphate donors. Tyrosine Protein Kinase,Tyrosine-Specific Protein Kinase,Protein-Tyrosine Kinase,Tyrosine Kinase,Tyrosine Protein Kinases,Tyrosine-Specific Protein Kinases,Tyrosylprotein Kinase,Kinase, Protein-Tyrosine,Kinase, Tyrosine,Kinase, Tyrosine Protein,Kinase, Tyrosine-Specific Protein,Kinase, Tyrosylprotein,Kinases, Protein-Tyrosine,Kinases, Tyrosine Protein,Kinases, Tyrosine-Specific Protein,Protein Kinase, Tyrosine-Specific,Protein Kinases, Tyrosine,Protein Kinases, Tyrosine-Specific,Protein Tyrosine Kinase,Protein Tyrosine Kinases,Tyrosine Specific Protein Kinase,Tyrosine Specific Protein Kinases
D011518 Proto-Oncogene Proteins Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity. Cellular Proto-Oncogene Proteins,c-onc Proteins,Proto Oncogene Proteins, Cellular,Proto-Oncogene Products, Cellular,Cellular Proto Oncogene Proteins,Cellular Proto-Oncogene Products,Proto Oncogene Products, Cellular,Proto Oncogene Proteins,Proto-Oncogene Proteins, Cellular,c onc Proteins
D011519 Proto-Oncogenes Normal cellular genes homologous to viral oncogenes. The products of proto-oncogenes are important regulators of biological processes and appear to be involved in the events that serve to maintain the ordered procession through the cell cycle. Proto-oncogenes have names of the form c-onc. Proto-Oncogene,Proto Oncogene,Proto Oncogenes
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D002471 Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill. Neoplastic Transformation, Cell,Neoplastic Cell Transformation,Transformation, Neoplastic Cell,Tumorigenic Transformation,Cell Neoplastic Transformation,Cell Neoplastic Transformations,Cell Transformations, Neoplastic,Neoplastic Cell Transformations,Neoplastic Transformations, Cell,Transformation, Cell Neoplastic,Transformation, Tumorigenic,Transformations, Cell Neoplastic,Transformations, Neoplastic Cell,Transformations, Tumorigenic,Tumorigenic Transformations
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000090063 Proto-Oncogene Mas A protein that is encoded by the MAS1 gene. It is a receptor for ANGIOTENSIN 1-7 and acts as an antagonist of ANGIOTENSIN-2 TYPE 1 RECEPTOR. C-Mas Protein,II-Proto-Oncogene Proteins, Cellular,Mas Protein,Mas1 Protein,Proto-Oncogene Protein Mas,Proto-Oncogene Proteins C-Mas-1,C Mas Protein,C-Mas-1, Proto-Oncogene Proteins,Cellular II-Proto-Oncogene Proteins,II Proto Oncogene Proteins, Cellular,Mas, Proto-Oncogene,Protein Mas, Proto-Oncogene,Protein, C-Mas,Protein, Mas,Protein, Mas1,Proteins, Cellular II-Proto-Oncogene,Proto Oncogene Mas,Proto Oncogene Proteins C Mas 1
D000310 Adrenal Gland Neoplasms Tumors or cancer of the ADRENAL GLANDS. Adrenal Cancer,Adrenal Gland Cancer,Adrenal Neoplasm,Cancer of the Adrenal Gland,Neoplasms, Adrenal Gland,Adrenal Cancers,Adrenal Gland Cancers,Adrenal Gland Neoplasm,Adrenal Neoplasms,Cancer, Adrenal,Cancer, Adrenal Gland,Cancers, Adrenal,Cancers, Adrenal Gland,Neoplasm, Adrenal,Neoplasm, Adrenal Gland,Neoplasms, Adrenal

Related Publications

M Santoro, and R Rosati, and M Grieco, and M T Berlingieri, and G L D'Amato, and V de Franciscis, and A Fusco
January 1992, Henry Ford Hospital medical journal,
M Santoro, and R Rosati, and M Grieco, and M T Berlingieri, and G L D'Amato, and V de Franciscis, and A Fusco
March 2008, Molecular and cellular endocrinology,
M Santoro, and R Rosati, and M Grieco, and M T Berlingieri, and G L D'Amato, and V de Franciscis, and A Fusco
January 1998, Irish journal of medical science,
M Santoro, and R Rosati, and M Grieco, and M T Berlingieri, and G L D'Amato, and V de Franciscis, and A Fusco
June 1996, Internal medicine (Tokyo, Japan),
M Santoro, and R Rosati, and M Grieco, and M T Berlingieri, and G L D'Amato, and V de Franciscis, and A Fusco
February 1998, Molecular and cellular endocrinology,
M Santoro, and R Rosati, and M Grieco, and M T Berlingieri, and G L D'Amato, and V de Franciscis, and A Fusco
February 1997, Deutsche medizinische Wochenschrift (1946),
M Santoro, and R Rosati, and M Grieco, and M T Berlingieri, and G L D'Amato, and V de Franciscis, and A Fusco
January 2001, Wiadomosci lekarskie (Warsaw, Poland : 1960),
M Santoro, and R Rosati, and M Grieco, and M T Berlingieri, and G L D'Amato, and V de Franciscis, and A Fusco
January 2007, Clinical laboratory,
M Santoro, and R Rosati, and M Grieco, and M T Berlingieri, and G L D'Amato, and V de Franciscis, and A Fusco
May 2000, Journal of endocrinological investigation,
M Santoro, and R Rosati, and M Grieco, and M T Berlingieri, and G L D'Amato, and V de Franciscis, and A Fusco
January 2015, Asian Pacific journal of cancer prevention : APJCP,
Copied contents to your clipboard!